GP for Me

Initial detection of CKD Algorithm

noreply@blogger.com (Dr Em) — Sat, 11 Aug 2012 10:33:00 +0000

From Chronic Kidney Disease Management in General Practice by Kidney Health Australia

Algorithm for management of hypertension in people with CKD

noreply@blogger.com (Dr Em) — Sat, 11 Aug 2012 08:41:00 +0000

From Chronic Kidney Disease Management in General Practice by Kidney Health Australia

ABCD2 Stroke and TIA Risk Assessment

noreply@blogger.com (Dr Em) — Sat, 11 Aug 2012 07:22:00 +0000

From Clinical Guidelines for Stoke and TIA Management, by National Stoke Foundation 2008

Algorithm for management of persistent microscopic haematuria

noreply@blogger.com (Dr Em) — Thu, 09 Aug 2012 10:41:00 +0000

From the booklet Chronic Kidney Disease (CKD) in General Practice by Kidney Health Australia endorsed by RACGP.

Diagnosis, assessment and initial management of Diabetes

noreply@blogger.com (Dr Em) — Tue, 07 Aug 2012 03:54:00 +0000

From Diabetes Management in General Practice 2011/2012 (Diabetes Australia)

What to recommend to a new diabetic:

Diet & Exercise - trial for 6 weeks (decrease saturated fats, eat small portions, change to low GI foods, exercise minimum 30mins 5 days per week). If unsuccessful, then...
Medications -

Oral hypoglycaemic agents. My my current favorites to use are metformin extended release, GLP-1 agonist ie Exenatide and DPP4 inhibitors ie Januvia or Galvus. Sulphonyureas is often used as a 2nd line agent after metformin but a local endocrinologist has advised that perhaps exenatide should be the next step due to lack of hypoglycaemic episodes as well as weight loss. Acarbose is also a very good agent but poorly tolerated due to excess bloating and flatulence.
Insulin. Lantus, Mixtard, Actrapid are my go-to insulins. Remember to also prescribe Glucagen Hypo Kit - 1 at work and 1 at home.

Antihypertensives

I tend to use Telmisartan ie Micardis, due to its excellent tolerability as well as positive effects on cholesterol, microalbuminuria and proteinuria, and reduced risk of myocardial infarctions, strokes and death from cardiovascular events. However, fosinopril ie Monopril is also a good option because there is no need to reduce the dose in renal impairment, but it does commonly cause in irritating cough

Cholesterol

Hypercholesteraemia: Statins ie lipitor or crestor. If not tolerable or need stronger control add exetimibe (Ezetrol), then resins such as cholestyramine (Questran) or colestipol (colestig) for hypercholesteraemia

Hypertriglyceridaemia: Fibrates such as fenofibrate (Lipidil) or gemfibrozil (lopid).

100mg Aspirin if no contraindication

Referrals

Diabetic educator - initially, then as needed
Dietitian - initially, then as needed
Podiatry - if issues with feet, or need help to cut toenails. Also worth getting it checked initially for potential problem areas
Optometry/ophthalmology at least every 2 years
Dentist - once to twice yearly checkup
Renal physician - consider if getting proteinuria
Endocrinologist - if sugars are difficult to control or significant complications, pregnancy, gestational diabetes, children/adolescents/adults with type 1 diabetes

Goals for optimum diabetic management

noreply@blogger.com (Dr Em) — Tue, 07 Aug 2012 00:57:00 +0000

From Diabetes Australia

noreply@blogger.com (Dr Em) — Mon, 06 Aug 2012 12:20:00 +0000

Flowchart for TFTs - for GPs

A nice summary of TFT interpretation - based on UK guidelines. Click above link for original website.

Thyroid nodule - Workup

noreply@blogger.com (Dr Em) — Mon, 06 Aug 2012 11:40:00 +0000

From American Thyroid Association - Thyroid Nodule

Follow up of benign thyroid nodules:

a) all benign thyroid nodules should be followed with serial US examinations 6–18 months after the initial FNA. If nodule size is stable (i.e., no more than a 50% change in volume or <20% increase in at least two nodule dimensions in solid nodules or in the solid portion of mixed cystic–solid nodules), the interval before the next follow-up clinical examination or US may be longer, e.g., every 3–5 years.
(b) If there is evidence for nodule growth either by palpation or sonographically (more than a 50% change in volume or a 20% increase in at least two nodule dimensions with a minimal increase of 2 mm in solid nodules or in the solid portion of mixed cystic–solid nodules), the FNA should be repeated, preferably with US guidance.

Subclinical Hyperthyroidism

noreply@blogger.com (Dr Em) — Mon, 06 Aug 2012 11:31:00 +0000

JCEM 2007